Vol.20 No.3

Case Report

Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis

Authors

Takeshi Kuroda1 , Daisuke Kobayashi1 , Hiroe Sato1 , Akihisa Oyanagi1 , Yoko Wada1 , Syuichi Murakami1 , Masaaki Nakano2 , Ichiei Narita1

  • Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Cyuuou-ku, Niigata 951-8510, Japan
  • Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Niigata 951-8518, Japan
Received:

30 October 2009

Accepted:

4 December 2009

Published online:

15 January 2010

Full Text

PDF　(member's only)

Abstract

We describe a 20-year-old female with systemic lupus erythematosus (SLE) who developed renal failure during continuous ambulatory peritoneal dialysis (CAPD). The patient was treated with mizoribine (MZR). MZR peak concentration was 1.8 μg/ml and was sufficient for clinical efficacy as measured by serological data. Treatment with MZR was safe and useful even while undergoing CAPD. Achieving optimal MZR blood concentration was important for treatment of SLE, even though the patient was in end-stage renal failure.

Key words

Systemic lupus erythematosus - Mizoribine - Chronic renal failure - Peritoneal dialysis